Methoden vergleichen
Prüfen Sie die ausgewählten Methoden nebeneinander; abweichende Zeilen sind hervorgehoben.
| Herzinsuffizienz Somatische Wahrnehmungsskala (HFSAS)× | Duke Activity Status Index (DASI)× | |
|---|---|---|
| Fachgebiet | Kardiologie | Kardiologie |
| Familie | Process / pipeline | Process / pipeline |
| Entstehungsjahr≠ | 2017 | 1989 |
| Urheber≠ | Steven R. Steinhubl | Mark A. Hlatky |
| Typ | Self-report questionnaire | Self-report questionnaire |
| Wegweisende Quelle≠ | Steinhubl, S. R., Mehta, P. K., & Ebner, G. S. (2017). The digital health revolution and consumer empowerment. Current Cardiology Reports, 19(11), 105. link ↗ | Hlatky, M. A., Boineau, R. E., Higginbotham, M. B., Lee, K. L., Mark, D. B., Califf, R. M., Cobb, F. R., & Pryor, D. B. (1989). A brief self-administered questionnaire to determine functional capacity (The Duke Activity Status Index). American Journal of Cardiology, 64(10), 651–654. DOI ↗ |
| Aliasnamen | HFSAS | DASI |
| Verwandt | 4 | 4 |
| Zusammenfassung≠ | The Heart Failure Somatic Awareness Scale (HFSAS) is a specialized measure that assesses heart failure patients' ability to recognize and accurately perceive early warning signs of disease worsening (somatic awareness), such as subtle changes in dyspnea, edema, weight, fatigue, or palpitations. Early recognition of decompensation signs enables prompt self-management action (diuretic adjustment, physician contact) and prevents costly hospitalizations. The HFSAS is essential in modern HF management, particularly with remote monitoring technologies and self-management support programs. | The Duke Activity Status Index (DASI) is a 12-item self-report questionnaire that estimates functional capacity—the maximum oxygen consumption (VO2 max) a patient can achieve—based on their ability to perform common daily activities. Developed by Hlatky and colleagues in 1989, the DASI provides a non-invasive assessment of exercise tolerance and cardiovascular fitness equivalent to formal exercise stress testing, making it invaluable for risk stratification, treatment planning, and prognosis in cardiac and pulmonary populations. |
| ScholarGateDatensatz ↗ |
|
|